SELLAS Life Sciences Group, Inc. (SLS)
NASDAQ: SLS · Real-Time Price · USD
5.36
+0.16 (3.08%)
Mar 20, 2026, 11:41 AM EDT - Market open

SLS Cash Flow Statement

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
FY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Net Income
-26.86-30.88-37.34-41.3-20.7
Stock-Based Compensation
1.961.562.091.731.01
Other Adjustments
0.60.560.4910.131.28
Change in Receivables
----1.13
Changes in Accounts Payable
-0.54-2.142.31.21-2.51
Changes in Accrued Expenses
-1.94-2.181.453.650.73
Changes in Unearned Revenue
-----5.6
Changes in Other Operating Activities
-1.6-2.32-0.410.78-1.36
Operating Cash Flow
-28.39-35.4-31.41-23.81-26.02
Purchases of Intangible Assets
---5.5-4.5-
Investing Cash Flow
---5.5-4.5-
Issuance of Common Stock
86.8246.8222.3524.0812.07
Repurchase of Common Stock
-0.53-0.06-0.03--
Net Common Stock Issued (Repurchased)
86.346.7622.3224.0812.07
Financing Cash Flow
86.346.7622.3224.0812.07
Net Cash Flow
57.9111.36-14.6-4.23-13.95
Free Cash Flow
-28.39-35.4-31.41-23.81-26.02
FCF Margin
----2380.90%-342.38%
Free Cash Flow Per Share
-0.26-0.58-1.13-1.23-1.68
Levered Free Cash Flow
-30.94-37.53-34-35.66-29.44
Unlevered Free Cash Flow
-32.35-38.16-34.52-36.31-33.75
Updated Dec 31, 2025. Data Source: Fiscal.ai. Standard template. Financial Sources.
SEC Filings: 10-K · 10-Q